Joshua Meyer, MD

Joshua Meyer, MD
This physician is not currently rated. Why?

Why is this doctor not rated?

Close

To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles. Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive evaluation and ratings from patients.

More about patient ratings
Request an Appointment

Call 888-369-2427

Request Online

Clinical Locations

Vice Chair, Translational Research, Department of Radiation Oncology

Professor, Department of Radiation Oncology

Specialties

Treatment Focus

Stereotactic Body Radiation Therapy (SBRT), Intensity Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), Radioembolization, MR-guided Focused Ultrasound, Re-irradiation, Pulsed Low Dose Rate (PLDR) radiation, Brachytherapy, Anal Cancer

Research Program

Treatment Philosophy

As technologies and treatments continue to advance, there are more and more options in the details of how each cancer patient is treated. I work with my colleagues in other disciplines to define the most appropriate treatment for each individual patient. For each individual I am treating with radiation, I make a concerted effort to survey the landscape of potential treatment choices that I am able to bring to a particular patient’s care to ensure that the most effective, precise and targeted approach is being used in every situation. This allows patients to get the maximum amount of benefit from treatment with as small a risk of complications as possible. 

Educational Background

  • Resident, Stich Radiation Center, Weill Cornell Medical Center, New York, NY
  • MD, University of Massachusetts Medical School, Worcester, MA, 2005
  • BA, Haverford College, Haverford, PA, 1998

Certifications

  • Board Certified, Radiation Oncology, American College of Radiology, 2011

Memberships

  • American College of Radiology (ACR)
  • American Society of Clinical Oncology (ASCO)
  • American Society of Therapeutic Radiation Oncology (ASTRO)

Honors & Awards

  • ARRO Educator of the Year, 2015
  • Clinical Fellow, ASCO/AACR Workshop on Methods in Clinical Cancer Research, 2009
  • Roentgen Resident/Fellow Research Award, 2009
  • Lang Research Award, New York Hospital of Queens Residents and Fellows Day, 2009
  • American Radium Society Travel Grant, 2009
  • ASCO Cancer Foundation Merit Award, American Society of Clinical Oncology, 2009
  • International Society of Gastrointestinal Oncology Conference Educational Grant, 2008

Rodney Malarchik

  • Pancreatic Cancer

[Treatment] is worthwhile because once you are on the other side, you have a promise of a future. That is impactful. You need to find a path through it if you can.

VIEW PATIENT STORY

Anthony Demidio

  • Colorectal Cancer

I’m 62 and I live in Bristol, Pa., with my wife Maryann. Between the two of us, we have four children and eight grandchildren (with another on the way). I also have a large extended family, and I work full time as a contractor. Needless to say, I’m a pretty busy guy!

VIEW PATIENT STORY

Nick Pifani

  • Pancreatic Cancer

I’m 45 and live in Delran, New Jersey, with my wife and two kids. I work as a vice president of business development for MasterCard, and in my spare time I love to run.

I’ve run marathons and completed an Ironman 70.3 (also known as a Half Ironman), which consists of a 1.2-mile swim, a 56-mile bike ride, and a 13.1-mile run. So, I’m no stranger to pain and discomfort.

VIEW PATIENT STORY

Alan Zlatkin

  • Pancreatic Cancer

Being defeated is a matter of perspective and will. I feel that no matter how serious the illness is, I can overcome it with the right help and the right attitude.

VIEW PATIENT STORY

Research Interests

My interests are in clinical research for gastrointestinal cancers. This includes the new application of radiation technology to increase surgical resectability and cure rates. It also includes outcomes work to determine which management strategies are the most effective for these patients.

Selected Publications

Meyer J.E., Reddy S., ASO author reflections: Neoadjuvant chemoradiation impacts the prognostic effect of surgical margin status in pancreatic adenocarcinoma. Ann Surg Oncol. 29(1): 364-365, 2022. PMC9036528. https://www.ncbi.nlm.nih.gov/pubmed/34091775.

Paly J.J., Deng M., Lee C.T., Hayes S.B., Galloway T.J., Hallman M.A., Weiss S.E., Horwitz E.M., Price R.A., Ma C.C., Meyer J.E., Pelvic reirradiation utilizing pulsed low-dose rate radiation therapy. Am J Clin Oncol. 43(10): 748-751, 2020. https://www.ncbi.nlm.nih.gov/pubmed/32769406.

Wong J.K., Handorf E., Lee D., Jain R., Zhang E., Cooper H.S., Farma J.M., Dotan E., Meyer J.E., Toxicity and outcomes in older versus younger patients treated with trimodality therapy for locally advanced rectal cancer. J Geriatr Oncol. 11(8): 1331-1334, 2020. PMC7606716. https://www.ncbi.nlm.nih.gov/pubmed/32381438.

LS Wang, T Shaikh, EA Handorf, JP Hoffman, SJ Cohen, JE Meyer. Dose Escalation With a Vessel Boost in Borderline Resectable Pancreatic Adenocarcinoma Treated With Neoadjuvant Chemoradiation. Practical  Radiation Oncology  90(1); 2015. PubMed

Shaikh T, Ruth K, Scoot WJ, Burtness BA, Cohen SJ, Konski AA, Cooper HS, Astsaturov I, Meyer JE.  “Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer.”  Ann Thorac Surg, 99(1):270-6, 2015 PubMed

Meyer JE, Panico VJ, Marconato HM, Sherr DL, Christos P, Pirog EC. “HIV positivity but not HPV/p16 status is associated with higher recurrence rate in anal cancer.” J Gastrointest Cancer, 44(4):450-5; 2013. PubMed

Meyer JE, Cohen SJ. “Beyond First-Line Therapy: Combining Chemotherapy and Radioembolization for Hepatic Colorectal Metastases.” J Nucl Med Radiat Ther  2:1-6; 2011 

Meyer JE, Sherr DL. “Reply to receptive anal intercourse as a potential risk factor for rectal cancer.” Cancer.  117:3284-5; 2011.

Meyer JE, Narang T, Schnoll-Sussman FH, Pochapin MB, Christos PJ, Sherr DL. “Increasing incidence of rectal cancer in patients aged younger than 40 years.” Cancer. 116:4354-9; 2010. PubMed

Meyer JE, Sherr DL. “When Less Is More, When Less Is Less: Local Excision in Early Rectal Cancer.” Gastrointest Cancer Res. 3(3): 123-4; 2009. PubMed... Expand

Additional Publications

My NCBI

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...
Resize Text

Related Articles

00 / 00